Assessment of the effects of pregabalin by the current perception threshold test in patients with chronic pruritus

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

CRIS

Registry ID

KCT0004215

Enrollment

Registered

2019-08-20

Start date

2017-10-19

Completion date

Unknown

Last updated

2019-08-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug : Pregabalin group : Olopatadine 5mg and bepotastine 10mg is taken orally twice a day for 4 weeks. Pregabalin 75mg is taken orally twice a day for later 2 weeks. Antihistamine group : Olopatadin

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Eligible participants were adults with chronic pruritus that persisted for more than 6 weeks and healthy individuals as a control group.

Exclusion criteria

Exclusion criteria: a history of diabetes mellitus, hepatobiliary disease, chronic renal failure, eczema, psoriasis, and other skin diseases, with overt inflammation improved by topical steroids or oral antihistamines, abnormal laboratory results, and an initial VAS score of lower than 3 or a duration of pruritus of less than 6 weeks

Design outcomes

Primary

Measure	Time frame
VAS score	—

Countries

Korea, Republic of

Contacts

Public ContactJAEIN LEE

National Medical Center

groundlee@nmc.or.kr+82-2-2260-7315

Outcome results